

1 **Development and experimental validation of an overlay mortar with**
2 **biocide activity**

3
4
5
6
7
8 J. M. Vaquero^a, V. Cugat^b, I. Segura^{b, c*}, M. A. Calvo^d, A. Aguado^b
9

10
11
12
13 ^a BASF Construction Chemicals, Ctra del Mig, 219, 08907 L'Hospitalet del Llobregat, Spain
14

15 ^b Department of Construction Engineering, Universitat Politècnica de Catalunya - Barcelona
16
17 Tech, C1, 08034, Barcelona, Spain
18

19
20 ^c Smart Engineering Ltd., C/Jordi Girona 1-3, Parc UPC – K2M, 08034, Barcelona, Spain
21

22 ^d Department of Animal Health and Anatomy, Faculty of Veterinary, Universitat Autònoma
23
24 de Barcelona, Edifici V, 08193, Bellaterra, Spain
25
26

27
28
29
30 **Abstract**
31

32
33 Biodeterioration of concrete by microorganism colonisation may be a problem in several
34
35 structures, especially in irrigation and hydroelectric canals. The main problem in such
36
37 structures is the proliferation of algae and cyanobacteria that affect the performance of the
38
39 structure, increase the maintenance costs and affects its durability. A research was conducted
40
41 to develop a novel cement-based material with biocide activity that can be used as an overlay
42
43 mortar in existing structures, such as canals and pipes. With this aim, ten commercial biocides
44
45 were evaluated in a laboratory campaign to assess the effectiveness of the compounds against
46
47 the microbial colonization of concrete. Both mono- and multicomponent formulations were
48
49 designed from the commercial products, to increase their antimicrobial effect obtaining a set
50
51
52
53

54
55 * Corresponding author: Ignacio Segura Pérez. Universitat Politècnica de Catalunya. Departament d'Enginyeria
56
57 de la Construcció. Carrer Jordi Girona 1-3, Edificio C1, despacho 202. E-08034 Barcelona. SPAIN. Email:
58
59 ignacio.segura@upc.edu. Tel.: +34-93-401-65-30. Fax: +34-93-405-41-35
60
61
62
63
64
65

23 of biocide formulations. The formulations were submitted to a flowchart process to determine
24 their influence on the physical properties of the concrete, evaluate the release of the actives,
25 and their antimicrobial efficiency both before and after accelerated aging processes. During
26 the campaign, some formulations were observed to diminish the strength of the concrete.
27 Such behaviour was normally due to the interaction of the active with the cement hydration
28 process. Other formulations showed a high release of active from the concrete in water,
29 compromising the durability of the treatment. In general, monocomponent formulations did
30 not succeed to fulfill all the requirements, thus multicomponent formulations were analysed.
31 One studied multicomponent formulation presented particularly good results in all properties
32 analysed. This product did not significantly change the properties of concrete and the release
33 of active in water from the concrete was low, while the antimicrobial effects were long
34 lasting.

36 **Keywords**

37 Biocide; Mortar; Cement; Bioreceptivity; Colonisation; Algae; Bacteria; Fungi

39 **1. Introduction**

40 Concrete is one of the most used construction materials because it has high structural
41 performance, long durability, and a relatively low cost. The surface of concrete is resistant to
42 corrosion and provides a physically and chemically stable environment that can be exposed to
43 potable water or wastewater; for this reason, it is commonly used in pipes and canals (Alum et
44 al., 2008). In these structures, microorganisms can easily colonise concrete and cause
45 biodeterioration of the material. The main problem in irrigation and hydroelectric canals is the
46 growth of algae and cyanobacteria among other microorganisms on the canal walls. This
47 biological growth creates many problems that are reflected in increased maintenance costs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48 The effective section of the canal is decreased and the roughness coefficient of the canal wall
49 is increased, which diminishes the water flow (Lancar and Krake, 2002). Some studies reflect
50 a decrease of 10% in the hydroelectric generation capacity because of algal growth
51 (Andrewartha et al., 2007; Perkins et al., 2009). Furthermore, it is worth noting that presence
52 of some types of fungi can have detrimental effects in concrete walls as well as can affect
53 production of certain cereals, as *Fusarium* (Giannantonio et al., 2009). Moreover, the
54 detachment of filamentous organisms such as green algae carries the risk of clogging and
55 plugging filters. Both the growth of these organisms on concrete and the required cleaning
56 activities to remove them from the walls cause erosion to the surface of the concrete. This
57 intensifies the porosity and roughness of the material and makes it more vulnerable to re-
58 colonisation.

59
60 Algal growth is usually preceded by concrete biofouling. This phenomenon is often grouped
61 in the literature into several stages that include an initial accumulation of adsorbed organics,
62 the settlement and growth of pioneering bacteria creating a biofilm matrix and the subsequent
63 succession of micro and macrofoulers (Chambers et al., 2006). Usually, bacteria play a
64 dominant role in the formation of this biofilm and further colonisation of larger
65 microorganisms (Wei et al., 2013).

66
67 Several antimicrobial treatments have been used in concrete and cement-based materials.
68 Conventional studied procedures involve the usage of water repellents, biocides, or both.
69 Water repellents slow the adsorption of water by reducing the surface energy and capillary
70 forces of the concrete, thus decreasing the bioreceptivity of the material. Biocides focus on
71 decreasing biological activity. While the use of hydrophobic compounds alone was shown to
72 be insufficient in inhibiting microbial growth, the application of a combination of both

73 treatments has been reported as effective (Urzì and De Leo, 2007; De Muynck et al., 2009).

74 The order of application of the different products influences the efficiency of the final

75 treatment; this must be considered to avoid negative effects (Malagodi et al., 2000; Nugari

76 and Salvadori, 2003; Moreau et al., 2008).

77

78 Biocide treatments have one of two mechanisms: the elimination of the microorganisms

79 already present on the material, and the prevention and control of microbial re-colonisation on

80 clean surfaces. Many compounds have been analysed and tested over the years, including

81 zeolites supporting heavy metal ions (such as copper and silver), zinc oxide, silver

82 nanoparticles, pyridine biocides, silver nitrate, and quaternary ammonium compounds, or

83 Quats (Urzì and De Leo, 2007; Alum et al., 2008; De Muynck et al., 2009; Eyssautier-Chuine

84 et al., 2015). Quats are most frequently used because they have good efficacy as algacides

85 (Nugari et al., 2009). Nevertheless, this issue is far from being solved from a scientifically

86 and technically point of view.

87

88 The main aim of this paper is to present the results obtained in a research devoted to the

89 development of cement-based materials with biocide activity to be used as a biocide mortar

90 layout in existing concrete structures (Vaquero, 2013; Aguado et al., 2014). Therefore,

91 different commercially available antimicrobial products were evaluated for effectiveness

92 against microbial colonisation in concrete. These products were chosen for cost-effectiveness,

93 non-toxicity, and capacity as disinfectants in other applications, such as floor and wall

94 coverings. Different combinations of the commercial biocides were considered to increase

95 their antimicrobial effect obtaining a set of biocide formulations. The experimental campaign

96 was designed to evaluate the influence of the incorporation of the biocide formulations in

97 concrete properties and their antimicrobial activity. Furthermore, the durability of the biocide

1 98 activity was also evaluated through accelerated aging processes. The performances of the
2 99 different combinations studied are shown and analysed, with special attention to the reasons
3
4 100 responsible for the failure of the formulations.
5
6
7 101

8 9 102 **2. Materials and methods**

10 103 **2.1 Concrete specimens**

11
12 104 Concrete specimens were fabricated with the dosage shown in Table 1. The cement selected
13
14 105 to produce the different mixtures was a CEM II A/V 42.5R. All aggregates were siliceous
15
16 106 with a low fraction of particles under 0.125 mm sieve. The largest aggregate size was selected
17
18 107 according to the size of the Petri dishes utilized for the microbiological tests. Furthermore, a
19
20 108 large water-to-cement (w/c) ratio of the mixes (0.7) was used to obtain samples with high
21
22 109 porosities that favoured microbiological colonisation. Lastly, a plasticiser additive (Pozzolith
23
24 110 475N, BASF Construction Chemicals) was added to each mixture based on percentage over
25
26 111 cement weight (% ocw). All concrete samples were made according to EN 12390-2 (AENOR,
27
28 112 2009a). The samples were cured in a curing chamber ($20^{\circ} \pm 2^{\circ}\text{C}$; $95 \pm 5\%$ relative humidity)
29
30 113 for 28 days.
31
32
33
34
35
36
37
38
39 114
40

41 115 Table 1. Concrete dosages for reference and biocide mixtures
42

43 44 Compound	45 46 Dosage (kg/m³)
47 48 Cement	49 50 350
51 52 Fine aggregate (0-5 mm)	53 54 1074
55 56 Coarse aggregate (5-12 mm)	57 58 724
59 60 Plasticiser	61 62 3.5 (1%)
63 64 Water	65 244

2.2 Design of biocide formulations

Ten commercially available antimicrobial products (Table 2) were tested during the experimental campaign. These products were chosen for cost-effectiveness, non-toxicity, and capacity as disinfectants in other applications, such as floor and wall coverings. The antimicrobial products shown in Table 2 were used to develop different formulations for cement-based biocides. These biocide formulations were composed of one (monocomponent) or several antimicrobial products (multicomponent) as well as incorporating different additives in some cases (see Table 3). Multicomponent formulations were designed to achieve as wide a spectrum of antimicrobial action as possible. The content of each component of the formulations is given between brackets, expressed as percentage of the formulation.

Table 2. General information on the different antimicrobial products evaluated

Number	Active	Commercial name	Effect	Physical state
1	bis(2-pyridylthio)zinc 1,1'-dioxide (Zinc pyrithione 10%)	ACTICIDE SR 1288®	Fungicide and bactericide	Liquid
2	1,2,3,6-Tetrahydro-N-(trichloromethylthio)phthalimide	BIOPOL D 212®	Fungicide	Powder
3	Dithio-2,2'-bis(benzmethylamide)	DENSIL P®	Fungicide and bactericide	Liquid
4	2-pyridinethiol-1-NaO + 1, 2-benzisothiazole-3 (2H) -one	P 24-81	Fungicide and bactericide	Powder
5	bis(2-pyridylthio)zinc 1,1'-dioxide (Zinc pyrithione 10%)	BC 98-56	Fungicide and bactericide	Powder
6	n-Butyl-1,2-benzisothiazolin-3-one	VANQUISH 100®	Fungicide, bactericide and algaecide	Liquid
7	Poly(hexamethylene biguanide) hydrochloride	VANTOCIL IB®	Bactericide	Liquid
8	2-octyl-2H-isothiazol-3-one + Terbutryn	ACTICIDE SR 1453®	Algaecide and fungicide	Powder
9	n-Tert-butyl-N-cyclopropyl-6-(methylthio)-1,3,5-triazine-2,4-diamine + 2 Octyl-2H-isothiazol-3-one	ACTICIDE MBP®	Bactericide and fungicide	Powder
10	2,4,4'-trichloro-2'-hydroxy-diphenyl ether	IRGASAN DP 300®	Bactericide and fungicide	Powder

131 Table 3. General information on the biocide formulations

	Formulation name	Active number	Additives
Monocomponent	BXT	1	Calcium filler (20%)
	BIOPOL D212	2	-
	DENSIL P	3	-
	P24-81	4	-
	BC 98-56	5	-
	VANQUISH 100	6	-
	VANTOCIL IB	7	-
	ACTICIDE MBP	9	-
	BXT/11	10	PG (59.7%), TIBP (0.3%), water (15%)
BXT/AB	10	PG (74.44%), TIBP (0.45%), BUBLEX® (0.11)	
Multicomponent	BXT/1	1 (16%), 8 (59%)	MOUSSEX® (4%), water (21%)
	BXT/5	1 (8%), 10 (3.45%)	PG (10%), PEG (10%), TIBP (0.15%), OPTIGEL CR® (1.5%)
	BXT/10P	9 (15%), 10 (4%)	MOUSSEX® (0.3%), Calcium filler (80.7)
	BXT/12C	1 (5.12%), 10 (5%)	PG (12.23%), PEG (77.34%), TIBP (0.21%), BUBLEX® (0.1%)
	PL-UV-H-2B	8 (30%), 10 (15%)	MOUSSEX® (4%), Calcium filler (51%)

132

133 As Table 3 shows, some additives were incorporated to improve the physical properties of the
134 mixture. MOUSSEX®, BUBLEX®, and tri-isobutyl phosphate (TIBP) are used as defoamer
135 compounds to avoid air entrapment in the concrete mix; propylene and polyethylene glycol
136 (PG and PEG, respectively) are used as solvents instead of water to allow the solubilisation of
137 the antimicrobial products and the collection of liquid admixtures; OPTIGEL CR® is an
138 activated bentonite product used for anti-settling and stabilizing in water-based systems.
139 Finally, calcium filler is used as a dispersive matrix for the biostatic agents. The biocide
140 formulations were incorporated in the concrete mix in different amounts, as listed in Table 4;
141 the dosage is expressed as percentage over dry weight of the mix (% odw). Concrete
142 specimens were fabricated for each formulation dosage. Furthermore, reference samples were
143 made for each biocide formulation without since cement samples may vary over time. These
144 quantities were chosen based on the recommendations of the manufacturers of the products.
145 Table 4 also provides information of the content of active principle in the formulations; in

146 case of multicomponent formulations, individual and total contents are given for each
 147 antimicrobial product.

148

149 Table 4. Dosage of the biocide formulations and active contents

Formulation name	Dosage (% odw)	Active content (kg/m ³)			
		A	B	Total	
Monocomponent	BXT	0.05	0.859	-	0.859
		0.15	2.578	-	2.578
	BIOPOL D212	0.1	2.148	-	2.148
		0.2	4.296	-	4.296
		0.3	6.444	-	6.444
	DENSIL P	0.2	4.296	-	4.296
		0.5	10.740	-	10.740
		1	21.480	-	21.480
		2	42.960	-	42.960
	P24-81	0.3	6.444	-	6.444
	BC 98-56	0.3	6.444	-	6.444
	VANQUISH 100	0.002	0.043	-	0.043
		0.013	0.279	-	0.279
		0.025	0.537	-	0.537
		0.037	0.795	-	0.795
		0.05	1.074	-	1.074
	VANTOCIL IB	0.3	6.444	-	6.444
		0.6	12.888	-	12.888
		1	21.480	-	21.480
	ACTICIDE MBP	0.1	2.148	-	2.148
		0.4	8.592	-	8.592
		0.8	17.184	-	17.184
	BXT/11	0.15	0.806	-	0.806
		0.18	0.967	-	0.967
0.2		1.074	-	1.074	
0.22		1.181	-	1.181	
BXT/AB	0.01	0.054	-	0.054	
	0.05	0.269	-	0.269	
	0.1	0.537	-	0.537	
	0.15	0.806	-	0.806	
BXT/1	2.5	8.592	31.683	40.275	
	3	10.310	38.020	48.330	
	3.5	12.029	44.356	56.385	
BXT/5	0.075	0.056	0.129	0.184	
	0.15	0.111	0.258	0.369	
	0.2	0.148	0.344	0.492	
	0.4	0.296	0.687	0.984	
BXT/10P	0.8	0.687	2.578	3.265	
	1	0.859	3.222	4.081	
BXT/12C	0.1	0.110	0.107	0.217	
	0.6	0.660	0.644	1.304	
PL-UV-H-2B	0.15	0.483	0.967	1.450	
	0.2	0.644	1.289	1.933	
	0.3	0.967	1.933	2.900	

150

151 **2.3 Experimental campaign**

152 The experimental campaign was designed as a flowchart, as described in Figure 1 with three
153 consecutive main phases. Firstly, the influence of the different biocide formulations on
154 physical properties of concrete was determined. Secondly, those biocide concretes that passed
155 the first phase were subjected to a release test to determine the amount of active released from
156 the sample. Finally, microbiological tests were conducted in those samples that passed the
157 previous phases. The evaluation of antimicrobial properties was conducted twice, before and
158 after an accelerated aging test, to simulate adverse conditions and thus estimate the durability
159 of the tested treatment.

160

161 Figure 1. Flowchart of the experimental campaign

162

163 **2.3.1 Physical characterisation of concrete specimens**

164 Concrete specimens were characterised to determine the influence of the biostatic
165 formulations on the physical properties of the samples. Several parameters were considered in
166 both the fresh and hardened state. Workability and density were characterised in the fresh
167 concrete. The workability of the mixes was determined according to the ISO 1920-2 standard
168 (ISO, 2005). The characterisation of the hardened concrete samples included density and
169 mechanical properties determinations (compressive and flexural strength). The compressive
170 and flexural strength measurements were made following EN 12390-4 and 5, respectively
171 (AENOR, 2009b; c).

172

173 **2.3.2 Release of active**

174 Following the physical characterization of the concrete samples, release tests were performed
175 to determine the amount of the active released from the samples. The method described in

176 prEN 16105:2010 (AENOR, 2010) is usually applied to evaluate leaching of substances from
177 coatings and paints. Thus, it was selected to evaluate the release of active from the concrete
178 samples, as the cement-based biocide developed is intended to be used as an overlay mortar
179 for existing structures. This method subjects the samples to wetting-drying cycles to simulate
180 the effects of rain and environmental conditions. After the wetting-drying cycles, the water
181 samples are analysed to determine the amount of active released from the samples.

182

183 Samples for the release tests were obtained from the same concrete dosages described
184 previously. All samples presented at least 100 cm² of surface area and with weights
185 characterised both before and after the tests. For each analysis, duplicate samples of each
186 biocide mixture were studied. Furthermore, one reference sample was also analysed. All
187 samples were maintained for 7 days at 23° ± 2° C at a relative humidity of 50 ± 5%. The
188 subsequent immersion process lasted 24 days. During that time, nine wetting-drying cycles
189 were performed on days 1, 3, 7, 9, 14, 16, 18, 22, and 24. Each cycle contained the following
190 steps: 1 h immersion, 4 h drying, 1 h immersion, and 48 h drying. At the end of the cycle, the
191 water samples were collected and analysed by HPLC analyses and pH measurements.

192

193 The amount of active present in the solution after the release tests can be expressed according
194 to Eq. (1). Here, M is the amount of active expressed in mg/m²·day, c is the measured
195 concentration of active in the eluate in mg/L, V_{real} is the real volume of eluate after each
196 immersion day in L, A is the effective surface area exposed to the releasing test in m², and t is
197 the day of immersion.

$$M = \frac{c \cdot V_{real}}{A \cdot t} \quad (1)$$

199

200 **2.3.3 Evaluation of antimicrobial properties**

201 The different concrete samples were tested to determine their antimicrobial properties both
 202 before and after accelerated aging processes to estimate the durability of the treatments.

203 Several samples from the different concrete mixes were exposed to suspensions containing
 204 different microorganisms. The characteristics of the microorganisms used are described in
 205 Table 5. The microorganisms were collected from different culture media from the American
 206 Type Culture Collection (ATCC) and the Sammlung von Algenkulturen Göttingen (SAG).

207
 208 Table 5. Microorganisms used for to evaluate antimicrobial properties and characteristics of
 209 incubation periods thereof

Type of microorganism	Microorganism	Reference code	Incubation period		
			Agar type	Temperature (°C)	Time (days)
Fungus	<i>Aspergillus niger</i>	ATCC 6275	Malt extract agar	25 ± 2	5-7
Bacteria	<i>Staphylococcus aureus</i>	ATCC 6538P	Nutrient agar	30 ± 2	2
Bacteria	<i>Escherichia coli</i>	ATCC 8739		30 ± 2	2
Algae	<i>Scenedesmus vaculatus</i>	SAG 211-8b	Kuhl solution	20 ± 2	21
Algae	<i>Stichococcus bacillaris</i>	SAG 379-1a		20 ± 2	21

210
 211 The concrete samples were located in Petri dishes containing agar media specialized for each
 212 microorganism. The concrete samples were of 10 mm thickness and variable sizes, obtained
 213 from the samples described in section 2.3. The different microorganism suspensions were
 214 spread over the agar surface. Each suspension contained at least 5×10^6 organisms per mL.

215 The Petri dishes with the concrete samples and the suspensions were incubated as detailed in
 216 Table 5. At the end of the incubation period, the antimicrobial properties of the samples were
 217 evaluated. The samples were visually analysed to determine the growth of the
 218 microorganisms and classified by the following scale: 0 – no visible growth of

19 microorganisms; 1 – slight observable growth of microorganisms; 2 – evident growth of
1
2 220 microorganisms and presence of spores.

3
4 221
5
6
7 222 As mentioned above, after the first evaluation of the antimicrobial properties an accelerated
8
9 223 aging process was conducted to simulate the adverse conditions concrete can experience, thus
10
11
12 224 evaluating antimicrobial efficiency over time. The exposure test Xenotest 150S was
13
14 225 performed. This test was designed to evaluate the durability of paints and varnishes, and
15
16
17 226 consists of an uninterrupted irradiation of the samples for 2000 h with 340 nm radiation at a
18
19 227 radiant flux of 0.5 W/m², in UNE-EN ISO 4892-2 (AENOR, 2014) standard conditions. This
20
21
22 228 treatment is equivalent to 6-8 months of continuous strong sunlight. By using ultraviolet
23
24 229 fluorescent lamps and irrigation sprinklers, the process simulates environmental wear accrued
25
26
27 230 over a much longer period than actually experienced. The samples exposed to the accelerated
28
29 231 aging process and others with the same characteristics without aging were evaluated a second
30
31
32 232 time with respect to antimicrobial properties, and the differences in the capacity of the
33
34 233 samples to inhibit microbial growth were compared and examined.

35
36 234
37
38
39 235 **3. Results and discussion**
40
41 236 **3.1 General evaluation**
42
43 237 During the experimental campaign, the biocide formulations shown in Table 3 were submitted
44
45
46 238 to the flowchart process described in section 2.2. Those that did not present good results in a
47
48
49 239 given phase were immediately discarded from the experiment to save time and cost. At first,
50
51 240 only monocomponent formulations were evaluated. None of them was able to pass the whole
52
53 241 evaluation process, as shown in Table 6. Some of the formulations failed in the physical
54
55
56 242 properties evaluation phase (BXT/AB, BXT/11, VANQUISH 100, DENSIL P and BC 98-56);
57
58
59
60
61
62
63
64
65

243 formulations BIOPOL D212 and VANTOCIL IB did not passed releasing tests; finally,
 244 ACTICIDE MBP, P24-82 and BXT were discarded after the antimicrobial test.

245
 246 Considering these results, multicomponent formulations were tested to increase the
 247 antimicrobial activity and/or to overcome the problems observed during the first evaluation
 248 phase. Five multicomponent formulations were designed and analysed. Only one of the
 249 multicomponent formulations (PL-UV-H-2B) presented good results during the complete
 250 evaluation process. Table 6 presents a summary of the phase at which the formulation was
 251 discarded.

252
 253 Table 6. Failure phases and qualification of each formulation during the experimental
 254 campaign

	Formulation	Failure phase
Monocomponent	BXT/AB	Physical properties
	BXT/11	Physical properties
	ACTICIDE MBP	Antimicrobial properties (before aging process)
	BIOPOL D212	Releasing test
	VANTOCIL IB	Releasing test
	VANQUISH 100	Physical properties
	DENSIL P	Physical properties
	P24-81	Antimicrobial properties (before aging process)
	BC 98-56	Physical properties
	BXT	Antimicrobial properties (after aging process)
Multicomponent	BXT/12C	Physical properties
	BXT/10P	Physical properties
	BXT/1	Physical properties
	BXT/5	Antimicrobial properties (before aging process)
	PL-UV-H-2B	None

258 **3.2 Physical characterisation**

259 Firstly, the results obtained by the monocomponent formulations will be analysed. Five out of
 260 ten of the monocomponent formulations affected the physical properties of the concrete
 261 samples, mainly with respect to strength. Only the results of these formulations will be
 262 analysed here. The results of mechanical performance of these samples are shown in Table 7,
 263 along with the measurements of workability and density in fresh state.

264

265 Table 7. Mechanical properties of the monocomponent formulations failing first phase tests

Formulation name	Dosage (% odw)	Flow (mm)	Fresh density (kg/m ³)	Mechanical properties (MPa)			
				Compressive strength		Flexural strength	
				1 d	28d	1d	28d
DENSIL P	0	154	2450	19.1	47.8	4.8	8.2
	0.2	154	2435	19.3	48.3	4.6	9.4
	0.5	155	2435	8.5	41.1	2.2	7.2
	1.0	155	2435	4.4	42.1	1.2	8.3
	2.0	159	2422	n.d.	34.2	n.d.	7.3
BC 98-56	0	150	2432	12.8	33.5	3.5	6.8
	0.3	135	2465	n.d.	36.6	n.d.	7.6
VANQUISH 100	0	155	2450	15.4	33.6	3.3	6.5
	0.002	152	2392	14.2	33.1	2.9	6.1
	0.013	152	2401	13.1	29.2	2.8	5.6
	0.025	153	2417	13.4	27.4	3.0	5.5
	0.037	156	2439	12.8	30.9	3.0	5.4
	0.050	150	2427	12.8	27.4	2.5	5.8
BXT/11	0	117	2389	15.5	35.1	3.2	5.6
	0.15	118	2005	5.3	16.0	2.1	3.3
	0.18	122	2004	7.2	21.4	2.5	5.2
	0.20	121	2122	6.9	20.9	2.7	5.3
	0.22	127	2174	9.6	24.3	2.4	5.8
BXT/AB	0	117	2389	15.5	35.1	3.2	5.6
	0.01	120	2420	15.1	29.9	2.6	5.4
	0.05	125	2395	14.8	34.3	2.8	5.4
	0.10	128	2467	13.0	31.8	2.3	5.0
	0.15	124	2397	11.9	29.8	2.1	4.9

266

267 The results shown in Table 7 direct evidence the biocide formulations affected the concrete
 268 samples in two different ways. The first phenomenon observed was the influence of the active

269 principles in the cement hydration process. Most of the formulations exhibited this
1
2 270 phenomenon. The formulations BXT/AB, VANQUISH 100 and DENSIL P mainly
3
4 271 influenced early-age properties of the concrete samples. Concrete samples made with these
5
6
7 272 formulations presented results similar to those from the reference concrete regarding
8
9 273 workability and density, with variations lower than 5% in these properties. However, the
10
11
12 274 mechanical resistances decreased significantly, especially at lower ages. The reduction of
13
14 275 compressive strength increases with increased biocide formulation dosages, e.g.: concrete
15
16
17 276 samples made with BXT/AB formulation reached a 23% reduction of compressive strength
18
19 277 with a dose of 0.15% at 1 day, and a 35% reduction of flexural strength at the same dose and
20
21
22 278 age. In this case, the active principles are retarding the cement hydration process thus
23
24 279 reducing compressive and flexural strengths in relation to the reference samples. The
25
26
27 280 strengths obtained at 28 days showed slight recovery, although they remained below the
28
29 281 reference value.

30
31 282
32
33
34 283 BC 98-56 formulation also influenced the cement hydration process but in a different way.
35
36 284 This formulation modified the workability of the concrete samples by increasing the viscosity
37
38
39 285 of the fresh mix. A strong diminution of the resistances at 24 h was observed and the samples
40
41 286 could not be demoulded. Mechanical properties at 28 days were higher than those of the
42
43
44 287 reference concrete were. This behaviour could be explained by the influence of the active
45
46 288 principle on the cement hydration process, generating smaller but more proliferate crystals.
47
48
49 289 Consequently, the crystallization process would be slower and the resistances would increase
50
51 290 with age.

52
53 291
54
55
56 292 The second phenomenon observed was air-entrapment, evidenced in concrete samples made
57
58 293 with BXT/11 formulation. This formulation was designed with the same active principle as
59
60
61
62
63
64
65

294 BXT/AB, but with a reduced amount of propylene glycol and water substituted to improve the
1
2 295 stability of the solution. With this reduction, the amount of defoamer compound was also
3
4 296 decreased; only TIBP was used. In these samples, significant reductions were observed in
5
6
7 297 their densities. The addition of IRGASAN DP 300® produced air entrapment in the concrete
8
9
10 298 mix and diminished the density, thus requiring increased amounts of defoamer to release
11
12 299 entrapped air. Another important aspect was observed regarding to the densities of the
13
14 300 antimicrobial samples. The increased amount of biostatic agent in the mix did not produce a
15
16
17 301 proportional reduction of the densities, but quite the opposite; as the content of biocide
18
19 302 increased, the density also increased. This phenomenon may result from the increased amount
20
21
22 303 of biostatic agent being accompanied by an increased amount of defoamer compounds in the
23
24 304 concrete, thus reducing air entrapment. The influence of the formulation on the densities of
25
26
27 305 the mixtures produced significant reductions in the strength values, with a maximum
28
29 306 diminution of 66% in compressive strength with a dose of 0.15% at 1 day.

30
31 307
32
33
34 308 Regarding the multicomponent formulations evaluated, most of them did not present good
35
36 309 results during the evaluation of their mechanical performance. This was the case for BXT/1,
37
38
39 310 BXT/10P, and BXT/12C; the compressive and flexural strengths of these compounds are
40
41 311 shown in Table 8, as well as the workability and density measurements in fresh state. A trend
42
43
44 312 in both compressive and flexural strengths of the concrete samples is observed; the decreases
45
46 313 in strength are directly proportional to the increases of biocide contents in the mixtures. The
47
48
49 314 controlling factor in this decrease of strength is again the influence of the active principles in
50
51 315 the cement hydration process. Minor influences are observed in workability and density in
52
53
54 316 fresh state of the concrete samples as compared with the reference samples. Nevertheless,
55
56 317 large reductions in compressive strength are observed for the samples containing BXT/1,

318 BXT/10P, and BXT/12C formulations. Furthermore, samples with BXT/1 formulation could
 319 not be demoulded at the age of 24 hours.

320

321 Table 8. Mechanical properties of the multicomponent formulations

Formulation name	Dosage (% odw)	Flow (mm)	Fresh density (kg/m ³)	Mechanical properties (MPa)			
				Compressive strength		Flexural strength	
				1 d	28d	1d	28d
BXT/1	0	157	2426	12.5	36.7	3.7	7.5
	0.4	150	2465	n.d.	34.0	n.d.	6.7
	0.45	153	2439	n.d.	31.2	n.d.	6.5
	0.5	149	2468	n.d.	34.3	n.d.	6.3
BXT/5	0	165	2343	15.8	42.3	4.8	8.7
	0.08	170	2337	14.9	40.5	4.3	8.1
	0.15	167	2381	15.1	40.0	3.8	8.4
	0.2	165	2330	14.5	39.0	3.5	7.9
	0.4	168	2327	14.0	39.0	3.3	7.7
BXT/10P	0	125	2473	19.1	35.0	4.8	7.2
	0.8	117	2266	10.3	30.6	2.8	6.1
	1	120	2200	8.2	29.0	2.5	6.0
BXT/12C	0	117	2389	12.8	33.5	3.5	6.8
	0.6	120	2420	8.1	28.4	2.8	5.6
	1	125	2395	6.2	22.7	2.3	4.4
PL-UV-H-2B	0	148	2523	14.3	37.1	4.0	9.4
	0.15	152	2501	12.7	36.9	3.5	8.6
	0.2	145	2479	11.3	35.7	2.8	8.2
	0.3	150	2484	14.0	34.9	3.2	8.5

322

323 Only BXT/12C and PL-UV-H-2B formulations did not significantly change the physical
 324 properties of the concrete mixtures. Both fresh and apparent densities are in the same range of
 325 values, with differences under 2%. Minor reductions in the fresh density of samples
 326 elaborated with the highest dosage of PL-UC-H-2B formulation are observed. This reduction
 327 is related with an air-entrapping process, since the formulation was designed as a solid
 328 powder because of the difficulties of obtaining a stable suspension of the antimicrobial
 329 products. Although minor variations of compressive and flexural strength are observed, these

330 are negligible and do not evidence shortcomings in the mechanical performances of the
1
2 331 concretes.

3
4 332

5
6
7 333

8 9 334 **3.3 Release of active**

10
11 335 Releasing tests were made in those monocomponent formulations that succeeded the first
12
13
14 336 phase of physical characterization (ACTICIDE MBP, BIOPOL D212, VANTOCIL IB, P24-
15
16
17 337 81, and BXT). The releasing curves of the actives from concrete samples containing each
18
19 338 formulation are shown in Figure 2; in the case of P24-81 formulation, separated curves are
20
21
22 339 shown for each active (NaP: 2-pyridinethiol-1-NaO; BIT: 1,2-benzisothiazole-3(2H)-one).

23
24 340 For each formulation, daily and accumulated concentrations are given on the right and left
25
26
27 341 side of the figure, respectively). According to the same procedure used in the physical
28
29 342 characterization tests, the formulations that did not present good results in this phase were
30
31 343 discarded, as occurred with the monocomponent formulations Biopol D212 and Vantocil IB
32
33
34 344 (see Figure 2b and 2c). Although the releasing levels of Biopol D212 are far from toxicity, as
35
36 345 the value considered detrimental for humans of this product is $LD_{50} > 9000$ ppm, this high
37
38
39 346 solubility in water could quickly decrease the antimicrobial efficiency of the treated concrete.
40
41 347 The formulation seemed excessively soluble for the intended purpose and thus it was
42
43
44 348 discarded. Similar behaviour was observed with the formulation Vantocil IB in the releasing
45
46 349 test. The amount of active released increases as the dosage of the antimicrobial mixture is
47
48
49 350 increased, for both formulations.

50
51 351

52
53 352 Figure 2. Releasing curves of the active from concrete fabricated with monocomponent
54
55
56 353 formulations: a) ACTICIDE MBP, b) BIOPOL D212, c) VANTOCIL IB, d) P24-81, and e)
57
58 354 BXT

355

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

356 Regarding the multicomponent formulations, releasing tests were made only in PL-UV-H-2B
357 formulations since BXT/5 formulation is comparable to monocomponent formulations
358 ACTICIDE MBP and BXT. The releasing curves of the active from concrete samples
359 containing the formulation PL-UV-H-2B are shown in Figure 3; separated curves are
360 provided for each active present in the formulation (OIT: 2-octyl-2H-isothiazol-3-one; TER:
361 terbutryn). As expected, an increase in the actives released is observed with increasing
362 dosages of the formulation. For the sample with 0.15% dosage of the formulation, the actives
363 are mainly released during the first 9 days of the test. Afterwards, only minor releasing is
364 observed. The sample with 0.2% dosage presents higher released quantities of actives
365 throughout the releasing test. An anomalous measurement at 14 days is much higher for OIT
366 than the rest (0.45 mg/m²). If this value is not considered, the total amount of active released
367 from the sample is proportional to the initial content of the active in the concrete sample.

368
369 Figure 3. Releasing curves of the active from concrete fabricated with PL-UV-H-2B
370 formulation

371
372 For the highest tested dosage of PL-UV-H-2B formulation (0.3%), the quantities of active
373 released are much larger than the ones for the other dosages. The release of active from the
374 sample during the first 7 days is approximately six times greater compared to the results of the
375 0.15% sample, thus increasing until the end of the process. The total active released from the
376 0.3% sample is more than nine times larger than that from the 0.15% sample. This behaviour
377 suggests possible interactions between the active and the cementitious matrix. However, as
378 the content of formulation is increased above 0.2%, there is more free active in the pore
379 solution; hence, the active released increases during the duration of the test. The total amount

380 of active released throughout the test is far below toxic values. The sample with the largest
1
2 381 content of formulation releases a total amount of 1.52 mg/m² of actives, which is equivalent
3
4 382 to 0.3 ppm. This antimicrobial product is considered toxic for humans at LD₅₀ > 2360 ppm,
5
6
7 383 which is almost four orders of magnitude larger than the total amount of active released from
8
9
10 384 the sample during the releasing test.

11 385

14 386 **3.4 Evaluation of the antimicrobial properties**

16
17 387 The final phase of the experimental campaign was only performed on those formulations that
18
19 388 had presented good results in both previous phases, as described in sections 3.2 and 3.3. Three
20
21 389 monocomponent formulations (ACTICIDE MBP, P 24-81, and BXT) were evaluated, but
22
23
24 390 none presented good results after the process. Two multicomponent formulations (BXT/5 and
25
26 391 PL-UV-H-2B) were also subjected to the microbiological test.

27
28
29 392

30
31 393 Firstly, the results obtained by concrete samples fabricated with ACTICIDE MBP formulation
32
33
34 394 will be presented. This monocomponent formulation was expected to have bactericide and
35
36 395 fungicide activity. Therefore, it was tested against three microorganisms (*Escherichia coli*,
37
38
39 396 *Staphylococcus aureus*, and *Aspergillus niger*). Figure 6 depicts images of the evaluation of
40
41 397 the antimicrobial tests performed with this formulation. The concrete samples show good
42
43
44 398 efficiency against *Staphylococcus aureus*, preventing biological growth on the surface with a
45
46 399 growth index of 0 in all treated samples; the reference sample presents a growth index of 2.
47
48
49 400 However, the concrete samples do not inhibit surface growth of *Escherichia coli* or
50
51 401 *Aspergillus niger*, presenting a growth index of 2 at all dosages. Since the antimicrobial
52
53 402 activity against two of the three microorganisms is negligible, the product is considered not
54
55
56 403 valid.

57
58 404

1
2 405 Figure 4. Effectiveness of concrete made with Acticide MBP formulation against different
3 406 microorganisms

4
5 407
6
7 408 Secondly, concrete samples made with P 24-81 formulation were analysed; the results of the
8
9 409 antimicrobial tests are shown in Figure 5. This formulation was also expected to present
10
11 410 bactericide and fungicide activity; it was tested against the same microorganisms as samples
12
13 411 made with ACTICIDE MBP formulation. The treated samples contained 0.3% odw. After the
14
15 412 microbiological test, the compound presented no antimicrobial properties against any
16
17 413 microorganism, with no inhibition of biological growth on the surface of the sample. The
18
19 414 visual analysis (see Figure 5) showed a growth index of 2 in all cases; hence, it was also
20
21 415 discarded before the accelerated aging process.
22
23
24
25

26 416
27
28
29 417 Figure 5. Effectiveness of concrete made with P 24-81 formulation against different
30
31 418 microorganisms

32
33 419
34
35
36 420 Finally, BXT formulation was analysed. This product was expected to have biocide and
37
38 421 fungicide activity. In initial antimicrobial tests, shown in Figure 6a, the product exhibits good
39
40 422 antimicrobial properties against both types of bacteria, with a growth index of 0 in every case.
41
42 423 Nevertheless, the effect against the *Aspergillus niger* fungus is only acceptable with the
43
44 424 dosage of 0.15% with a growth index of 1; this index has a value of 2 for the sample with the
45
46 425 lowest dose of 0.05%. The results are considered sufficient for validity, and the samples were
47
48 426 submitted to the accelerated aging test. A second antimicrobial test was conducted following
49
50 427 the same procedure. After aging, the inhibition of bacterial growth is retained, as seen in
51
52 428 Figure 6b, with a growth index of 0 in all cases. However, the antimicrobial activity against
53
54
55
56
57
58
59
60
61
62
63
64
65

429 *Aspergillus niger* is not preserved, as the growth index reaches 2 with both dosages; thus, the
1
2 430 product is considered not valid.
3

4
5 431
6
7 432 Figure 6. Effectiveness of concrete made with BXT formulation against different
8
9
10 433 microorganisms: a) before and b) after the accelerated aging process
11

12 434
13
14 435 Regarding the multicomponent formulations, BXT/5 formulation is composed of the active
15
16
17 436 principles IRGASAN DP 300® and ACTICIDE SR 1288®, and it was tested against all
18
19 437 microorganisms listed in Table 5 to evaluate its antimicrobial efficiency. After the biological
20
21
22 438 tests, the treatment showed great efficiency against the bacteria *Staphylococcus aureus* and
23
24 439 the two types of algae, *Scenedesmus vacuolatus* and *Stichococcus bacillaris*, with growth
25
26
27 440 indexes of 0 for all dosages, as seen in Figure 7. In these cases, no biological growth occurred
28
29 441 on the surfaces, and inhibition halos surrounding the samples were observed. However, the
30
31
32 442 formulation did not present antimicrobial activity against *Escherichia coli* at any dose. This
33
34 443 may be due to the low content of ACTICIDE SR 1288® in the mixtures; BXT, which had the
35
36 444 same active principle but in greater amounts, presented highly antimicrobial behaviour. The
37
38
39 445 growth indexes against this microorganism with BXT/5 were 2 in all cases (see Figure 7). The
40
41 446 treatment was also inefficient against the fungus *Aspergillus niger*, reaching only an
42
43
44 447 acceptable level of activity, with a growth index of 1, at the highest dose (0.4%). At all other
45
46 448 doses, the growth index was 2, with no inhibition of biological growth. The unsatisfactory
47
48
49 449 behaviour of the treatment against *Escherichia coli* and *Aspergillus niger* justified the
50
51 450 discarding of the treatment without accelerated aging.
52

53 451
54
55
56 452 Figure 7. Effectiveness of concrete made with BXT/5 formulation against different
57
58 453 microorganisms: a) before and b) after the accelerated aging process
59
60
61
62
63
64
65

454

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

455 Finally, concrete samples made with PL-UV-H-2B formulation were analysed. Figure 8a
456 shows the results of microorganism colonisation after the incubation period of the
457 formulation. As noted in section 3.1, because the formulation is expected to present algacide,
458 bactericide, and fungicide activity, the compound was tested against all microorganisms listed
459 in Table 5 to evaluate its antimicrobial efficiency. The concrete samples present efficiency
460 against all microorganisms evaluated at all dosages; it prevents biological growth on the
461 surface and, in most cases, forms an inhibition halo surrounding the sample. With both
462 bacteria and algae, the concrete shows high antimicrobial activity with growth indexes of 0 in
463 all cases. With *Aspergillus niger*, higher formulation dosages of 0.2 and 0.3% are required to
464 obtain the same effect, as the lowest dose of 0.1% presents a growth index of 1 with no
465 inhibition halo surrounding the sample surface. The growth indexes for the reference samples
466 against the different microorganisms vary from 1 to 2.

467
468 Figure 8. Effectiveness of concrete made with PL-UV-H-2B formulation against different
469 microorganisms: a) before and b) after the accelerated aging process

470
471 According to the results of the initial antimicrobial test, the formulation PL-UV-H-2B was
472 considered valid and the samples were then subjected to the accelerated aging test. A second
473 antimicrobial test was conducted; images of the microbiological cultures are shown in Figure
474 8b. The antimicrobial activities against both bacteria and algae prevail after the aging process,
475 although larger inhibition halos surrounding the samples are observed at higher dosages of the
476 formulation. The growth index in all cases is zero. For the efficiency against fungal growth, a
477 slight loss of the antimicrobial activity is perceived because the inhibition halo is not formed

1 478 at any dosage. However, no biological growth occurs on the concrete samples; the growth
2 479 index is 1 for the samples with different biocide doses.
3

4 480

7 481 **4. Conclusions**

8
9 482 Fifteen biocide formulations were studied during this campaign to assess their biocide effects
10
11
12 483 when incorporated into concrete. These formulations were elaborated from different
13
14 484 commercially available antimicrobial products that were chosen for cost-effectiveness, non-
15
16
17 485 toxicity, and capacity as disinfectants in other applications, such as floor and wall coverings.
18
19 486 The biocide formulations were composed of one (monocomponent) or more antimicrobial
20
21
22 487 products (multicomponent) as well as incorporating different additives in some cases.
23

24 488

25
26 489 A three-phase process was performed to evaluate the physical properties, release of active and
27
28
29 490 antimicrobial properties of the concrete samples incorporating the different formulations. The
30
31
32 491 study showed that monocomponent formulations were insufficient to inhibit biological growth
33
34 492 in concrete without either significant detriment to the mechanical properties of the material or
35
36 493 losing efficient biostatic activity after a short period. To obtain a long-lasting effect against a
37
38
39 494 wide spectrum of microorganisms, the use of multicomponent formulations was necessary.
40

41 495

42
43 496 The use of existing commercial products such as Vanquish 100®, Densil P®, and BC 98-56
44
45
46 497 presented significant reductions in the mechanical resistances of concrete, typically with
47
48
49 498 influences during the hardening process. The formulations BXT/AB and BXT/11, which
50
51 499 incorporated IRGASAN DP 300®, also showed decreases in the strengths of the concrete.
52

53 500 This active principle, in certain compositions, caused a decrease in density through air
54
55
56 501 entrapment in the concrete mix. Some multicomponent formulations, such as BXT/12C,
57
58 502 BXT/10P, and BXT/1, also presented poor performance regarding mechanical properties. The
59
60
61
62
63
64
65

1 503 effect of the biostatic agents in the cement hydration process was the main reason for the
2 504 mechanical degradation of the concrete, especially at low ages.

3
4 505
5
6
7 506 Many of the formulations affected significantly the physical and mechanical properties of the
8
9 507 concrete samples, thus presenting lower mechanical performances. Two different behaviour
10
11
12 508 were observed. According to the results obtained, some formulations presented an interaction
13
14 509 of the actives with the cement hydration process. The low mechanical performance of the
15
16
17 510 samples at early ages may be related with the retardation of the hydration reactions.
18
19 511 Furthermore, air-entrapping was also observed. The formulations Vanquish 100®, Densil P®,
20
21
22 512 and BC 98-56, as well as BXT/AB and BXT/11, which incorporated IRGASAN DP 300®,
23
24 513 were discarded from the evaluation process.

25
26 514
27
28
29 515 The addition of the chemicals Biopol D212® and Vantocil IB® did not affect the strengths of
30
31 516 the concrete mixtures. However, when submitted to release tests, the modified samples
32
33
34 517 presented high solubility in water. This behaviour implied a rapid loss of antimicrobial
35
36 518 activity, which would compromise the duration of protection.

37
38
39 519
40
41 520 In the microbiological tests, the chemicals ACTICIDE MBP® and P 24-81 presented poor
42
43
44 521 results with almost no inhibition of biological growth. BXT offered good results against both
45
46 522 types of bacteria and the tested fungus before the accelerated aging process. However, after
47
48
49 523 aging, the activity against the fungus was not maintained. The multicomponent formulation
50
51 524 BXT/5 showed a high antimicrobial efficiency against both algae species and the bacteria
52
53 525 *Staphylococcus aureus*. Despite these results, the treatment did not present any biocide effect
54
55
56 526 against *Escherichia coli* and *Aspergillus niger*.

57
58 527
59
60
61
62
63
64
65

1 528 Among all the formulations evaluated, the formulation PL-UV-H-2B was the only one to
2 529 succeed in all the evaluation process. This multicomponent formulation, when mixed with
3
4 530 concrete, did not affect the physical or mechanical properties of the material. Only slight
5
6
7 531 reductions in density, compressive strength, and flexural strength were observed in
8
9
10 532 comparison with those of the reference samples, although the reductions were not significant.

11 533
12
13
14 534 Concerning the release tests, the quantity of active released by this formulation was very low.
15
16
17 535 The quantities released are approximately four orders of magnitude below the amount that
18
19 536 may be considered toxic for humans. This result also indicates a greater duration of the
20
21
22 537 biostatic effect of the treatment.

23
24 538
25
26 539 Moreover, concrete samples fabricated with PL-UV-H-2B formulation demonstrated high
27
28
29 540 effectiveness in antimicrobial tests against algae, fungi, and bacteria, both before and after
30
31
32 541 accelerated aging processes. The compound prevented biological growth in concrete, and in
33
34 542 most cases formed inhibition halos surrounding the samples.

35
36 543
37
38
39 544 **Acknowledgements**
40
41 545 The authors acknowledge the economic support provided by the Spanish Ministry of
42
43
44 546 Economy and Competitiveness through Project BIA2013-49106-C2-1-R. Furthermore, the
45
46 547 authors wish to thank the company BASF Construction Chemicals for the help provided to the
47
48
49 548 development of this work.

50
51 549
52
53 550 **References**
54
55
56 551 AENOR, 2009a. UNE-EN 12390-2:2009 Testing hardened concrete - Part 2: Making and
57
58 552 curing specimens for strength tests
59
60
61
62
63
64
65

553 AENOR, 2009b. UNE-EN 12390-3:2009 Testing hardened concrete - Part 3: Compressive
1
2 554 strength of test specimens
3
4 555 AENOR, 2009c. UNE-EN 12390-5:2009 Testing hardened concrete - Part 5: Flexural
5
6
7 556 strength of test specimens
8
9
10 557 AENOR, 2010. prEN 16105:2010 Paints and varnishes - Leaching of substances from
11
12 558 coatings - Laboratory immersion method
13
14 559 AENOR, 2014. UNE-EN ISO 4892-2:2014 Plastics - Methods of exposure to laboratory light
15
16
17 560 sources - Part 2: Xenon-arc lamps
18
19 561 Aguado, A., Segura, I., Vaquero, J.M., Servos, F., 2014. Additive to inhibit biological growth
20
21
22 562 in concrete structures and use, Spanish Patent reference number P201431036 (under review).
23
24 563 Alum, A., Rashid, A., Mobasher, B., Abbaszadegan, M., 2008. Cement-based biocide
25
26 564 coatings for controlling algal growth in water distribution canals. Cement & Concrete
27
28
29 565 Composites, 30: 839-847.
30
31 566 Andrewartha, J.M., Sargison, J.E., and Perkins, K.J., 2007. The effect of Gomphonema and
32
33
34 567 filamentous algae streamers on hydroelectric canal capacity and turbulent boundary layer
35
36 568 structure. 16th Australasian Fluid Mechanics Conference.
37
38
39 569 Chambers, L.D., Stokes, K.R., Walsh, F.C., and Wood, R.J.K., 2006. Modern approaches to
40
41 570 marine antifouling coatings. Surface and Coatings Technology 201: 3642–3652.
42
43
44 571 De Muynck, W., Maury Ramirez, A., De Belie, N., 2009. Evaluation of strategies to prevent
45
46 572 algal fouling on white architectural and cellular concrete. International Biodeterioration &
47
48
49 573 Biodegradation, 63: 679-689.
50
51 574 Eyssautier-Chuine, S., Vaillant-Gaveau, N., Gommeaux, M., Thomachot-Schneider, C.,
52
53
54 575 Pleck, J., Fronteau, G., 2015. Efficacy of different chemical mixtures against green algal
55
56 576 growth on limestone: A case study with *Chlorella vulgaris*. International Biodeterioration &
57
58 577 Biodegradation, 103: 59-68.
59
60
61
62
63
64
65

578 Giannantonio, D.J., Kurth, J.C., Kurtis, K.E., and Sobecky, P. A., 2009. Effects of concrete
1
2 579 properties and nutrients on fungal colonization and fouling. *International Biodeterioration and*
3
4
5 580 *Biodegradation*, 63: 252–259.
6
7 581 ISO, 2005 ISO 1920-2:2005. Testing of concrete - Part 2: Properties of fresh concrete.
8
9
10 582 Lancar, L., and Krake, K., 2002. *Aquatic Weeds and their Management*. International
11
12 583 Commission on Irrigation and Drainage.
13
14 584 Malagodi, M., Nugari, M.P., Altieri, A., Lonati, G., 2000. Effects of combined application of
15
16 585 biocides and protectives. In: Fassina, V. (Ed.), 9th International Congress on Deterioration and
17
18 586 Conservation of Stone. Elsevier, Amsterdam, the Netherlands, 225-233.
19
20
21 587 Moreau, C., Vergès-Belmin, V., Leroux, L., Oriol, G., Fronteau, G., Barbin, V., 2008. Water-
22
23 588 repellent and biocide treatments: assessment of the potential combinations. *Journal of Cultural*
24
25
26 589 *Heritage*, 9: 394–400.
27
28
29 590 Nugari, M.P., Salvadori, O., 2003. Biocides and treatment of stone: limitations and future
30
31 591 prospects. In: Koestler, R.J., Koestler, V.H., Charola, E.A.E., Nieto-Fernandez, F.E. (Eds.),
32
33 592 *Art, Biology and Conservation: Biodeterioration of Works of Art*. The Metropolitan Museum
34
35 593 of Art, New York, USA, 519–535.
36
37
38 594 Nugari, M.P., Pietrini, A.M., Caneva, G., Imperi, F., Visca, P., 2009. Biodeterioration of
39
40 595 mural paintings in a rocky habitat: the Crypt of the Original Sin (Matera, Italy). *International*
41
42 596 *Biodeterioration & Biodegradation*, 63: 705-711.
43
44
45 597 Perkins, K. J., Sargison, J., and Hallegraeff, G. M., 2009. Diatom fouling problems in a
46
47 598 Tasmanian hydro canal, including the description of *Gomphonema Tarraleahae* sp. nov.
48
49 599 *Diatom Research*, 24 (2): 377-391.
50
51
52 600 Urzì, C., De Leo, F., 2007. Evaluation of the efficiency of water-repellent and biocide
53
54 601 compounds against microbial colonisation of mortars. *International Biodeterioration &*
55
56 602 *Biodegradation*, 60: 25-34.
57
58
59
60
61
62
63
64
65

- 603 Vaquero, J. M., 2013. Microorganism-concrete interactions: evaluation methods and possible
1
2 604 solutions. PhD Thesis. Department of Construction Engineering, Universitat Politècnica de
3
4 605 Catalunya - Barcelona Tech. <http://www.tdx.cat/handle/10803/116930>
5
6
7 606 Wei, S., Jiang, Z., Liu, H., Zhou, D., and Sanchez-Silva, M., 2013. Microbiologically induced
8
9 607 deterioration of concrete - A Review. Brazilian Journal of Microbiology, 44(4): 1001–1007.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Concrete dosages for reference and biocide mixtures

Compound	Dosage (kg/m³)
Cement	350
Fine aggregate (0-5 mm)	1074
Coarse aggregate (5-12 mm)	724
Plasticiser	3.5 (1%)
Water	244

Table 2. General information on the different antimicrobial products evaluated

Number	Active	Commercial name	Effect	Physical state
1	bis(2-pyridylthio)zinc 1,1'-dioxide (Zinc pyrithione 10%)	ACTICIDE SR 1288®	Fungicide and bactericide	Liquid
2	1,2,3,6-Tetrahydro-N-(trichloromethylthio)phthalimide	BIOPOL D 212®	Fungicide	Powder
3	Dithio-2,2'-bis(benzmethylamide)	DENSIL P®	Fungicide and bactericide	Liquid
4	2-pyridinethiol-1-NaO + 1, 2-benzisothiazole-3 (2H) -one	P 24-81	Fungicide and bactericide	Powder
5	bis(2-pyridylthio)zinc 1,1'-dioxide (Zinc pyrithione 10%)	BC 98-56	Fungicide and bactericide	Powder
6	n-Butyl-1,2-benzisothiazolin-3-one	VANQUISH 100®	Fungicide, bactericide and algacide	Liquid
7	Poly(hexamethylene biguanide) hydrochloride	VANTOCIL IB®	Bactericide	Liquid
8	2-octyl-2H-isothiazol-3-one + Terbutryn	ACTICIDE SR 1453®	Algaecide and fungicide	Powder
9	n-Tert-butyl-N-cyclopropyl-6-(methylthio)-1,3,5-triazine-2,4-diamine + 2 Octyl-2H-isothiazol-3-one	ACTICIDE MBP®	Bactericide and fungicide	Powder
10	2,4,4'-trichloro-2'-hydroxy-diphenyl ether	IRGASAN DP 300®	Bactericide and fungicide	Powder

Table 3. General information on the biocide formulations

	Formulation name	Active number	Additives
Monocomponent	BXT	1	Calcium filler (20%)
	BIOPOL D212	2	-
	DENSIL P	3	-
	P24-81	4	-
	BC 98-56	5	-
	VANQUISH 100	6	-
	VANTOCIL IB	7	-
	ACTICIDE MBP	9	-
	BXT/11	10	PG (59.7%), TIBP (0.3%), water (15%)
	BXT/AB	10	PG (74.44%), TIBP (0.45%), BUBLEX® (0.11)
Multicomponent	BXT/1	1 (16%), 8 (59%)	MOUSSEX® (4%), water (21%)
	BXT/5	1 (8%), 10 (3.45%)	PG (10%), PEG (10%), TIBP (0.15%), OPTIGEL CR® (1.5%)
	BXT/10P	9 (15%), 10 (4%)	MOUSSEX® (0.3%), Calcium filler (80.7)
	BXT/12C	1 (5.12%), 10 (5%)	PG (12.23%), PEG (77.34%), TIBP (0.21%), BUBLEX® (0.1%)
	PL-UV-H-2B	8 (30%), 10 (15%)	MOUSSEX® (4%), Calcium filler (51%)

Table 4. Dosage of the biocide formulations and active contents

Formulation name		Dosage (% odw)	Active content (kg/m ³)		
			A	B	Total
Monocomponent	BXT	0.05	0.859	-	0.859
		0.15	2.578	-	2.578
	BIOPOL D212	0.1	2.148	-	2.148
		0.2	4.296	-	4.296
		0.3	6.444	-	6.444
	DENSIL P	0.2	4.296	-	4.296
		0.5	10.740	-	10.740
		1	21.480	-	21.480
		2	42.960	-	42.960
	P24-81	0.3	6.444	-	6.444
	BC 98-56	0.3	6.444	-	6.444
	VANQUISH 100	0.002	0.043	-	0.043
		0.013	0.279	-	0.279
		0.025	0.537	-	0.537
		0.037	0.795	-	0.795
		0.05	1.074	-	1.074
	VANTOCIL IB	0.3	6.444	-	6.444
		0.6	12.888	-	12.888
		1	21.480	-	21.480
	ACTICIDE MBP	0.1	2.148	-	2.148
0.4		8.592	-	8.592	
0.8		17.184	-	17.184	
BXT/11	0.15	0.806	-	0.806	
	0.18	0.967	-	0.967	
	0.2	1.074	-	1.074	
	0.22	1.181	-	1.181	
BXT/AB	0.01	0.054	-	0.054	
	0.05	0.269	-	0.269	
	0.1	0.537	-	0.537	
	0.15	0.806	-	0.806	
Multicomponent	BXT/1	2.5	8.592	31.683	40.275
		3	10.310	38.020	48.330
		3.5	12.029	44.356	56.385
	BXT/5	0.075	0.056	0.129	0.184
		0.15	0.111	0.258	0.369
		0.2	0.148	0.344	0.492
		0.4	0.296	0.687	0.984
	BXT/10P	0.8	0.687	2.578	3.265
		1	0.859	3.222	4.081
	BXT/12C	0.1	0.110	0.107	0.217
		0.6	0.660	0.644	1.304
	PL-UV-H-2B	0.15	0.483	0.967	1.450
0.2		0.644	1.289	1.933	
0.3		0.967	1.933	2.900	

Table 5. Microorganisms used for to evaluate antimicrobial properties and characteristics of incubation periods thereof

Type of microorganism	Microorganism	Reference code	Incubation period		
			Agar type	Temperature (°C)	Time (days)
Fungus	<i>Aspergillus niger</i>	ATCC 6275	Malt extract agar	25 ± 2	5-7
Bacteria	<i>Staphylococcus aureus</i>	ATCC 6538P	Nutrient agar	30 ± 2	2
Bacteria	<i>Escherichia coli</i>	ATCC 8739		30 ± 2	2
Algae	<i>Scenedesmus vacuolatus</i>	SAG 211-8b	Kuhl solution	20 ± 2	21
Algae	<i>Stichococcus bacillaris</i>	SAG 379-1a		20 ± 2	21

Table 6. Failure phases and qualification of each formulation during the experimental campaign

	Formulation	Failure phase
Monocomponent	BXT/AB	Physical properties
	BXT/11	Physical properties
	ACTICIDE MBP	Antimicrobial properties (before aging process)
	BIOPOL D212	Releasing test
	VANTOCIL IB	Releasing test
	VANQUISH 100	Physical properties
	DENSIL P	Physical properties
	P24-81	Antimicrobial properties (before aging process)
	BC 98-56	Physical properties
BXT	Antimicrobial properties (after aging process)	
Multicomponent	BXT/12C	Physical properties
	BXT/10P	Physical properties
	BXT/1	Physical properties
	BXT/5	Antimicrobial properties (before aging process)
	PL-UV-H-2B	None

Table 7. Mechanical properties of the monocomponent formulations failing first phase tests

Formulation name	Dosage (% odw)	Flow (mm)	Fresh density (kg/m ³)	Mechanical properties (MPa)			
				Compressive strength		Flexural strength	
				1 d	28d	1d	28d
DENSIL P	0	154	2450	19.1	47.8	4.8	8.2
	0.2	154	2435	19.3	48.3	4.6	9.4
	0.5	155	2435	8.5	41.1	2.2	7.2
	1.0	155	2435	4.4	42.1	1.2	8.3
	2.0	159	2422	n.d.	34.2	n.d.	7.3
BC 98-56	0	150	2432	12.8	33.5	3.5	6.8
	0.3	135	2465	n.d.	36.6	n.d.	7.6
VANQUISH 100	0	155	2450	15.4	33.6	3.3	6.5
	0.002	152	2392	14.2	33.1	2.9	6.1
	0.013	152	2401	13.1	29.2	2.8	5.6
	0.025	153	2417	13.4	27.4	3.0	5.5
	0.037	156	2439	12.8	30.9	3.0	5.4
	0.050	150	2427	12.8	27.4	2.5	5.8
BXT/11	0	117	2389	15.5	35.1	3.2	5.6
	0.15	118	2005	5.3	16.0	2.1	3.3
	0.18	122	2004	7.2	21.4	2.5	5.2
	0.20	121	2122	6.9	20.9	2.7	5.3
	0.22	127	2174	9.6	24.3	2.4	5.8
BXT/AB	0	117	2389	15.5	35.1	3.2	5.6
	0.01	120	2420	15.1	29.9	2.6	5.4
	0.05	125	2395	14.8	34.3	2.8	5.4
	0.10	128	2467	13.0	31.8	2.3	5.0
	0.15	124	2397	11.9	29.8	2.1	4.9

Table 8. Mechanical properties of the multicomponent formulations

Formulation name	Dosage (% odw)	Flow (mm)	Fresh density (kg/m ³)	Mechanical properties (MPa)			
				Compressive strength		Flexural strength	
				1 d	28d	1d	28d
BXT/1	0	157	2426	12.5	36.7	3.7	7.5
	0.4	150	2465	n.d.	34.0	n.d.	6.7
	0.45	153	2439	n.d.	31.2	n.d.	6.5
	0.5	149	2468	n.d.	34.3	n.d.	6.3
BXT/5	0	165	2343	15.8	42.3	4.8	8.7
	0.08	170	2337	14.9	40.5	4.3	8.1
	0.15	167	2381	15.1	40.0	3.8	8.4
	0.2	165	2330	14.5	39.0	3.5	7.9
	0.4	168	2327	14.0	39.0	3.3	7.7
BXT/10P	0	125	2473	19.1	35.0	4.8	7.2
	0.8	117	2266	10.3	30.6	2.8	6.1
	1	120	2200	8.2	29.0	2.5	6.0
BXT/12C	0	117	2389	12.8	33.5	3.5	6.8
	0.6	120	2420	8.1	28.4	2.8	5.6
	1	125	2395	6.2	22.7	2.3	4.4
PL-UV-H-2B	0	148	2523	14.3	37.1	4.0	9.4
	0.15	152	2501	12.7	36.9	3.5	8.6
	0.2	145	2479	11.3	35.7	2.8	8.2
	0.3	150	2484	14.0	34.9	3.2	8.5

Figure 1. Flowchart of the experimental campaign

Figure 2. Releasing curves of the active from concrete fabricated with monocomponent formulations: a) ACTICIDE MBP, b) BIOPOL D212, c) VANTOCIL IB, d) P24-81, and e) BXT

Figure 3. Releasing curves of the active from concrete fabricated with PL-UV-H-2B formulation

Figure 4. Effectiveness of concrete made with Acticide MBP formulation against different microorganisms

Figure 5. Effectiveness of concrete made with P 24-81 formulation against different microorganisms

Figure 6. Effectiveness of concrete made with BXT formulation against different microorganisms: a) before and b) after the accelerated aging process

Figure 7. Effectiveness of concrete made with BXT/5 formulation against different microorganisms: a) before and b) after the accelerated aging process

Figure 8. Effectiveness of concrete made with PL-UV-H-2B formulation against different microorganisms: a) before and b) after the accelerated aging process

Figure 1




Figure 2a





Figure 2b





Figure 2c





Figure 2d





Figure 2e





Figure 3





Figure 4













Microorganism	Formulation content (% odw)			
	Reference	0.1	0.4	0.8
<i>Escherichia coli</i>				
<i>Staphylococcus aureus</i>				
<i>Aspergillus niger</i>				

Figure 5
















Microorganism	Formulation content (% odw)	
	Reference	0.3
<i>Escherichia coli</i>		
<i>Staphylococcus aureus</i>		
<i>Aspergillus niger</i>		

Figure 6

a)

Microorganism	Formulation content (% odw)		
	Reference	0.05	0.15
<i>Escherichia coli</i>			
<i>Staphylococcus aureus</i>			
<i>Aspergillus niger</i>			

b)










Microorganism	Formulation content (% odw)		
	Reference	0.05	0.15
<i>Escherichia coli</i>			
<i>Staphylococcus aureus</i>			
<i>Aspergillus niger</i>			

Figure 7

















































Microorganism	Formulation content (% odw)				
	Reference	0.075	0.15	0.2	0.4
<i>Escherichia coli</i>					
<i>Staphylococcus aureus</i>					
<i>Aspergillus niger</i>					
<i>Stichococcus bacillaris</i> <i>Scenedesmus vaculatus</i>					

Figure 8

a)

Microorganism	Formulation content (% odw)			
	Reference	0.15	0.2	0.3
<i>Escherichia coli</i>				
<i>Staphylococcus aureus</i>				
<i>Aspergillus niger</i>				
<i>Stichococcus bacillaris</i> <i>Scenedesmus vaculatus</i>				

b)

Microorganism	Formulation content (% odw)			
	Reference	0.15	0.2	0.3
<i>Escherichia coli</i>				
<i>Staphylococcus aureus</i>				
<i>Aspergillus niger</i>				
<i>Stichococcus bacillaris</i> <i>Scenedesmus vaculatus</i>	